Last reviewed · How we verify

Transversus Abdominis Plane

Centre Hospitalier Universitaire, Amiens · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

Transversus Abdominis Plane is a Small molecule drug developed by Centre Hospitalier Universitaire, Amiens. It is currently FDA-approved.

The Transversus Abdominis Plane (TAP) block is a regional anesthesia technique used to manage postoperative pain, particularly in procedures such as minimally invasive left-sided colectomy. It involves injecting local anesthetics into the TAP space, which can be guided by ultrasound, to block pain signals from the abdominal viscera.

At a glance

Generic nameTransversus Abdominis Plane
SponsorCentre Hospitalier Universitaire, Amiens
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Transversus Abdominis Plane

What is Transversus Abdominis Plane?

Transversus Abdominis Plane is a Small molecule drug developed by Centre Hospitalier Universitaire, Amiens.

Who makes Transversus Abdominis Plane?

Transversus Abdominis Plane is developed and marketed by Centre Hospitalier Universitaire, Amiens (see full Centre Hospitalier Universitaire, Amiens pipeline at /company/centre-hospitalier-universitaire-amiens).

What development phase is Transversus Abdominis Plane in?

Transversus Abdominis Plane is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing